Beneficial effects of naringenin in liver diseases: Molecular mechanisms
Erika Hernández-Aquino, Pablo Muriel, Laboratory of Experimental Hepatology, Department of Pharmacology, Cinvestav-IPN, Mexico City 07000, Mexico
Author contributions: All authors equally contributed to this paper with the conception and design of the study, the literature review and analysis, the drafting and critical revision and editing of the manuscript, and with their final approval of the final version.
Supported by National Council of Science and Technology (Conacyt) of Mexico, No. 253037.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Pablo Muriel, PhD, Research Scientist, Laboratory of Experimental Hepatology, Department of Pharmacology, Cinvestav-IPN, Av. Instituto Politécnico Nacional 2508, Apartado postal 14-740, Mexico City 07000, Mexico. email@example.com
Telephone: +52-55-57473303 Fax: +52-55-57473394
Received: March 7, 2018
Peer-review started: March 8, 2018
First decision: March 29, 2018
Revised: April 4, 2018
Accepted: April 16, 2018
Article in press: April 16, 2018
Published online: April 28, 2018